Skip to main content

Month: May 2024

ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the first quarter ended March 31, 2024 and provided a corporate strategic update. First Quarter 2024 and Subsequent HighlightsMarch 2024: Significantly strengthened the company’s intellectual property portfolio related to an intragastric balloon system. Specifically, received...

Continue reading

Nokia Corporation: Repurchase of own shares on 15.05.2024

Nokia CorporationStock Exchange Release15 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 15.05.2024 Espoo, Finland – On 15 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows:Trading venue (MIC Code) Number of shares Weighted average price / share, EUR*XHEL 409,679 3.58CEUX – –BATE – –AQEU – –TQEX – –Total 409,679 3.58* Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation...

Continue reading

Terra Balcanica Announces Share Consolidation Effective Date

Vancouver, British Columbia, May 15, 2024 (GLOBE NEWSWIRE) — Terra Balcanica Resources Corp. (“Terra” or the “Company”) (CSE:TERA; FRA:UB1) announces that, further to the Company’s press release on May 8th, 2024, the consolidation of the outstanding common shares of the Company (each, a “Common Share”) on the basis of one post-Consolidation Common Share for every three pre-Consolidation Common Shares is anticipated to be made effective for trading purposes on Friday, May 17th, 2024 (the “Effective Date”). It is anticipated that the Common Shares will begin trading on the CSE on a post-Consolidation basis at market open on the Effective Date. The new CUSIP of the Common Shares will be 88089G202 and the new ISIN will be CA88089G2027. Shareholders with physical certificates will receive a letter of transmittal from Computershare...

Continue reading

Caisse Française de Financement Local EMTN 2024-6

Paris, 15 May 2024 Caisse Française de Financement Local has decided to issue on 17 May 2024 – Euro 500,000,000 fixed rate Obligations Foncières due 17 May 2039. A Stabilisation Manager has been named in the applicable Final Terms. The Base Prospectus dated 12 June 2023 and the supplements to the Base Prospectus dated 22 September 2023, 23 February 2024 and 10 April 2024 relating to the Euro Medium Term Notes Programme approved by the Autorité des Marchés Financiers are available on the website of the issuer (www.caissefrancaisedefinancementlocal.fr), at the registered office of the issuer: 112-114, avenue Emile Zola, 75015 Paris, France, and at the office of the paying agent indicated in the Base Prospectus. The Final Terms relating to the issue will be available on the website of the AMF (www.amf-france.org) and of the Luxembourg Stock...

Continue reading

AB Science reports its revenues for the year 2023 and provides an update on its activities

         PRESS RELEASE AB SCIENCE PRESENTS ITS FINANCIAL INFORMATION AS OF DECEMBER 31, 2023 AND THE KEY EVENTS OF THE PERIODClinical developmentContinuation of the conditional marketing authorisation application procedures with the European Medicines Agency (EMA) and Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) First complete bone marrow response in an acute myeloid leukemia patient in its AB8939 Phase I/II clinical trial New clinical development program for masitinib in sickle cell disease, among the winning projects to be funded under the sixth call for “Hospital-University Research in Health” (Recherche Hospitalo-Universitaire en santé) projects, part of the Future Investments Program Strengthening of intellectual property protection for masitinib in ALS, mastocytosis and prostate...

Continue reading

Nilfisk reports Q1 2024 results: Solid organic growth and robust financial performance in line with plan

  Nilfisk, a leading global provider of professional cleaning products and services, reported its Q1 2024 results today with solid organic growth and gross margin increase. Revenue was 259.0 mEUR, up 2.6 mEUR compared with Q1 2023. Organic growth for Q1 2024 was 3.7%. The EBITDA margin before special items (bsi) was 13.2%, leading to an EBITDA before special items of 34.2 mEUR. René Svendsen-Tune, CEO of Nilfisk comments on the Q1 results: “Nilfisk delivered a solid set of results in line with plan for Q1 2024. Stabilization in EMEA and a positive change in US momentum delivered volume growth for our Professional Business. We also saw our Service Business continue to grow, alongside a strong rebound from the Consumer Business. Also, we are delighted to announce that we have retained our Gold EcoVadis status”. Nilfisk delivered a significant...

Continue reading

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand. Gross profit increased from ($55.9 thousand) to $51.0 thousand.WASHINGTON, May 15, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, reported today their financial results for the first fiscal quarter of the 2024 year, ended March 31, 2024. Financial Highlights for the Quarter Ended March 31, 2024:Net product revenues increased approximately 515% from $17.17 thousand for the first quarter of 2023 to approximately $105.7 thousand for first quarter of 2024; the Company credits growth from domestic commercial sales of ARAKODA®. The Company achieved a gross profit of approximately $51.0 thousand in the first quarter of...

Continue reading

Pinnacle Bankshares Corporation Announces Quarterly Cash Dividend of 25 Cents per Share

ALTAVISTA, Va., May 15, 2024 (GLOBE NEWSWIRE) — Pinnacle Bankshares Corporation (“Pinnacle” or the “Company”) (OTCQX: PPBN), the one-bank holding company for First National Bank (the “Bank”), announced today that its Board of Directors declared a cash dividend of $0.25 per share on May 14, 2024, payable June 7, 2024, to shareholders of record as of May 24, 2024. The $0.25 per share cash dividend is equal to the $0.25 dividend paid last quarter and marks the forty-seventh consecutive quarter that a dividend has been declared. “Pinnacle is pleased to provide a cash dividend of $0.25 per share to our shareholders this quarter,” stated Aubrey H. Hall, III, President and Chief Executive Officer for both the Company and the Bank. Mr. Hall further commented, “This return on investment is consistent with our prior cash dividend, despite...

Continue reading

Genius Group Announces 2023 Financial Results, 150% Pro Forma Revenue Growth to $70.4 million

Singapore, May 15, 2024 (GLOBE NEWSWIRE) — Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading provider of AI-powered, digital-first education solutions, announced today its financial results for the year ended December 31, 2023. Business Highlights for Fiscal 20232023 audited revenue increased 27% to $23.1 million from $18.2 million in 2022. Pro forma 2023 revenue increased 150% to $70.4 million from $28.1 million in 2022, including revenue from the FatBrain AI transaction. Students and users increased 24% to 5.5 million from 4.4 million in 2022. Gross profit increased to $11.9 million or 52% of revenue compared to $8.6 million, or 47% of revenue in 2022. Net loss after tax reduced 90% to ($5.7) million compared to ($56.0) million in 2022. On a pro forma basis, net loss...

Continue reading

Star Equity Holdings to Release First Quarter 2024 Financial Results on May 20th

OLD GREENWICH, Conn., May 15, 2024 (GLOBE NEWSWIRE) — Star Equity Holdings, Inc. (Nasdaq: STRR; STRRP), (“Star Equity” or the “Company”), a diversified holding company, announced today that it will release its financial results for the first quarter ended March 31, 2024, before the market opens on Monday, May 20, 2024. A conference call is scheduled for 10:00 a.m. ET (7:00 a.m. PT) on May 20, 2024, to discuss the results and management’s outlook. The call may be accessed by dialing:Toll Free: 1-833-630-1956 International: 1-412-317-1837A simultaneous webcast of the call may be accessed online from the Events & Presentations link, on the Investor Relations page of the Star Equity website at: https://www.starequity.com/events-and-presentations/presentations. An archived replay of the webcast will be available shortly after...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.